ES2085329T3 - Agente anticanceroso proteico. - Google Patents

Agente anticanceroso proteico.

Info

Publication number
ES2085329T3
ES2085329T3 ES90301639T ES90301639T ES2085329T3 ES 2085329 T3 ES2085329 T3 ES 2085329T3 ES 90301639 T ES90301639 T ES 90301639T ES 90301639 T ES90301639 T ES 90301639T ES 2085329 T3 ES2085329 T3 ES 2085329T3
Authority
ES
Spain
Prior art keywords
modified
recognition protein
cell recognition
cancer agent
toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90301639T
Other languages
English (en)
Inventor
Allen Oliff
Deborah D Jones
Gwynneth M Edwards
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2085329T3 publication Critical patent/ES2085329T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE CONSIGUE LA TOXINA PE40 MODIFICADA MEDIANTE ELIMINACION DE AL MENOS DOS DE SUS CUATRO AMINO ACIDOS DE CISTEINA RESIDUAL Y SE CONSIGUEN MOLECULAS HIBRIDAS CONTENIENDO LA PE40 MODIFICADA ENLAZADA CON UNA PROTEINA RECONOCEDORA DE CELULAS, QUE PUEDE SER UN ANTICUERPO, UN FACTOR DE CRECIMIENTO, UNA HORMONA, UNA LINFOQUINA, U OTRA PROTEINA POLIPEPTIDA RECONOCEDORA DE CELULAS, PARA LAS CUALES EXISTE UN RECEPTOR CELULAR ESPECIFICO, POR LO QUE LA TOXINA PE40 MODIFICADA SE DIRIGE A CELULAS DEL TIPO DE LAS QUE TENGAN RECEPTORES PARA LA PROTEINA RECONOCEDORA DE CELULAS ENLAZADA CON LA PE40 MODIFICADA.
ES90301639T 1989-02-17 1990-02-15 Agente anticanceroso proteico. Expired - Lifetime ES2085329T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31254089A 1989-02-17 1989-02-17
US38909289A 1989-08-03 1989-08-03
US44918789A 1989-12-21 1989-12-21

Publications (1)

Publication Number Publication Date
ES2085329T3 true ES2085329T3 (es) 1996-06-01

Family

ID=27405603

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90301639T Expired - Lifetime ES2085329T3 (es) 1989-02-17 1990-02-15 Agente anticanceroso proteico.

Country Status (18)

Country Link
EP (1) EP0383599B1 (es)
JP (2) JPH07106159B2 (es)
KR (1) KR0169729B1 (es)
AT (1) ATE133993T1 (es)
AU (1) AU617039B2 (es)
CA (1) CA2010256C (es)
CY (1) CY1987A (es)
DE (1) DE69025211T2 (es)
DK (1) DK0383599T3 (es)
ES (1) ES2085329T3 (es)
FI (1) FI102383B1 (es)
GR (1) GR3019836T3 (es)
HK (1) HK15597A (es)
IE (1) IE71934B1 (es)
IL (1) IL93425A (es)
NO (1) NO300595B1 (es)
NZ (1) NZ232564A (es)
PT (1) PT93178B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631200B2 (en) * 1989-02-17 1992-11-19 Merck & Co., Inc. Production of modified pe40
JPH0829101B2 (ja) * 1989-04-21 1996-03-27 アメリカ合衆国 組換え抗体―毒素融合タンパク質
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
GB2246779B (en) * 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
AUPM959894A0 (en) * 1994-11-22 1994-12-15 Crc For Biopharmaceutical Research Pty Ltd Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4
WO1998029453A1 (fr) * 1996-12-27 1998-07-09 Mochida Pharmaceutical Co., Ltd. Medicaments diriges vers la membrane cellulaire
AU7553698A (en) * 1997-05-12 1998-12-08 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Method and construct for inhibition of cell migration
GB0008802D0 (en) * 2000-04-10 2000-05-31 Univ London Molecule
CA2571781C (en) * 2004-06-28 2015-05-12 Yeda Research And Development Co. Ltd Chimeric proteins and uses thereof
CN105766069B (zh) 2013-11-20 2019-04-16 株式会社村田制作所 多层布线基板及具备该多层布线基板的探针卡
WO2017061449A1 (ja) * 2015-10-05 2017-04-13 国立研究開発法人産業技術総合研究所 がん細胞の検出方法、がん細胞内に物質を導入するための試薬、及びがん治療用組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
JPH0829101B2 (ja) * 1989-04-21 1996-03-27 アメリカ合衆国 組換え抗体―毒素融合タンパク質

Also Published As

Publication number Publication date
EP0383599B1 (en) 1996-02-07
DE69025211T2 (de) 1996-09-19
CY1987A (en) 1997-09-05
IL93425A0 (en) 1990-11-29
GR3019836T3 (en) 1996-08-31
CA2010256A1 (en) 1990-08-17
CA2010256C (en) 2000-07-25
HK15597A (en) 1997-02-14
EP0383599A2 (en) 1990-08-22
NO900758D0 (no) 1990-02-16
PT93178B (pt) 1996-04-30
AU617039B2 (en) 1991-11-14
NO900758L (no) 1990-08-20
PT93178A (pt) 1990-08-31
IE71934B1 (en) 1997-03-12
KR900012626A (ko) 1990-09-01
FI102383B (fi) 1998-11-30
EP0383599A3 (en) 1991-03-27
AU4994690A (en) 1990-08-23
KR0169729B1 (ko) 1999-01-15
ATE133993T1 (de) 1996-02-15
JPH07106159B2 (ja) 1995-11-15
NZ232564A (en) 1992-08-26
JPH07278200A (ja) 1995-10-24
JP2510846B2 (ja) 1996-06-26
DE69025211D1 (de) 1996-03-21
DK0383599T3 (da) 1996-08-05
NO300595B1 (no) 1997-06-23
IL93425A (en) 1999-08-17
FI900783A0 (fi) 1990-02-16
IE900587L (en) 1990-08-17
FI102383B1 (fi) 1998-11-30
JPH02276590A (ja) 1990-11-13

Similar Documents

Publication Publication Date Title
ATE80166T1 (de) Verfahren zur isolierung rekombinanter polypeptide in biologisch aktiver form.
DE3650751T2 (de) Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
ATE171216T1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
ATE88572T1 (de) Antikoerper gegen polypeptide, die gegen peptide oder proteine mit mindestens teilweise bekannter aminosaeure oder kodierender nukleotidsequenz komplementaer sind und diesbezuegliches aufbauverfahren.
ES2085329T3 (es) Agente anticanceroso proteico.
PT94633A (pt) Metodo para a desnaturacao oxidante de analitos de proteina
SE8007074L (sv) Glukagonfragment jemte dess anvendning
ES2062029T3 (es) Procedimiento de purificacion de proteinas.
ES2109225T3 (es) Anticuerpos, su produccion y uso.
EP0293827A3 (en) Assay for leishmaniasis
ATE103973T1 (de) Gamma-atriales, natriuretisches polypeptid erkennende monoklonale antikoerper, solche antikoerper produzierende hybridome und deren herstellung und verwendung.
KR880006359A (ko) 사람의 tiits를 제조하기 위한 중간물질로서의 균일한 양 tiits 및 이의 용도

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 383599

Country of ref document: ES